Individualized targeted therapy for glioblastoma: Fact or fiction?

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 40-44

  Weller, Michael ^a   Stupp, Roger ^b   Hegi, Monika ^b   Wick, Wolfgang ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

angiogenesis; Glioblastoma; IDH; MGMT; molecular; therapy

Indexed keywords

ALPHA INTEGRIN; BETA3 INTEGRIN; BETA5 INTEGRIN; BEVACIZUMAB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; GENE MUTATION; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STEM CELL;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DECISION MAKING; GLIOBLASTOMA; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856728163     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318243f6c9     Document Type: Review

References (49)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114:97-109. (Pubitemid 47103521)
2. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses ofhigh-grade glioma predict prognosis, delineate a pattern of disease progres-sion, and resemble stages in neurogenesis. Cancer Cell. 2006;9: 157-173. (Pubitemid 43357943)
3. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110.
4. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related ''self-renewal'' signature and high epidermal growth factor receptor expres-sion associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015-3024.
5. Gaspar N, Marshall L, Perryman L, et al. MGMT-independent temo-zolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Res. 2010; 70:9243-9252.
6. Kim TM, Huang W, Park R, et al. A developmental taxonomy of glio-blastoma defined and maintained by micro RNAs. Cancer Res. 2011; 71:3387-3399.
7. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a Cp G island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-522.
8. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as mole-cular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002-6007.
9. Mehta M, Wang M, Aldape K, et al. Clinical, molecular, and molecular-clinical profile (MCP) exploratory subset analysis of RTOG 0525: a phase III trial comparing standard (std) adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule for glioblastoma (GBM). In: European Multidisciplinary Cancer Congress. 2011. Abstract 18.
10. Van den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype in anaplastic oligodendroglial brain tumors is a better pre-dictor of survival than MGMT methylation in anaplastic oligodendro-glioma: areport from EORTC study 26951. Clin Cancer Res. 2011;17: 7148-7155.
11. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and response to temozolomide in glioblastoma. N Engl J Med. 2005;352: 997-1003. (Pubitemid 40349502)
12. Hegi ME, Sciuscio D, Murat A, et al. Epigenetic deregulation of DNA repair and its potential for therapy. Clin Cancer Res. 2009;15: 5026-5031
13. The Cancer Genome Atlas Consortium. Comprehensive genomic charac-terization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-1068.
14. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-1812.
15. Lambeck A, Leffers N, Hoogeboom BN, et al. P53-specific T cell re-sponses in patients with malignant and benign ovarian tumors: implica-tions forp53 basedimmunotherapy. Int J Cancer. 2007;121:606-614. (Pubitemid 46986494)
16. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508-2518. (Pubitemid 46606332)
17. Wischhusen J, Naumann U, Ohgaki H, et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent cell de-ath. Oncogene. 2003;22:8233-8245. (Pubitemid 37485516)
18. Weinmann L, Wischhusen J, Demma MJ, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008; 15:718-729. (Pubitemid 351405077)
19. Gan HK, Kaye AH, Luwor RB. The EGFRv III variant in glioblastoma multiforme. JClin Neurosci. 2009;16:748-754.
20. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97:880-887. (Pubitemid 41417939)
21. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. NEngl J Med. 2005;353:2012-2024. (Pubitemid 41609094)
22. Van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glio-blastoma: EORTC Brain Tumor Group study 26034. J Clin Oncol. 2009;27:1268-1274.
23. Eisenstat DD, Nabors LB, Mason WP, et al. A phase II study ofdaily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J Clin Oncol. 2011;29[suppl]:Abstract 2010.
24. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diag-nosed glioblastoma multiforme. J Neurooncol. 2010;98:93-99.
25. Hegi ME, Diserens AC, Bady P, et al. Pathway analysis ofglioblas-toma tissue after preoperative treatment with the EGFR tyrosine ki-nase inhibitor gefitinib-a phase II trial. Mol Cancer Ther. 2011;10: 1102-1112.
26. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722-4729.
27. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methyla-tion in malignant gliomas: ready for personalized medicine? Nature Rev Neurol. 2010;6:39-51.
28. Stupp R, Hegi ME, Mason WP, et al. Effects ofradiotherapy with con-comitant and adjuvant temozolomide versus radiotherapy alone on sur-vival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
29. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial ofsequential radiochemotherapy ofanaplastic gliomawith PCVor temozolomide. J Clin Oncol. 2009;27:5874-5880.
30. Van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group study 26951. J Clin Oncol. 2009; 27:5881-5886.
31. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astroctytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of glio-mas. Acta Neuropathol. 2010;120:707-718.
32. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64:628-634.
33. Weller M, Platten M, Roth P, et al. Geriatric neuro-oncology: from mythology to biology. Curr Opin Neurol. 2011;24:599-604.
34. Malmstrom A, Grønberg BH, Stupp R, et al. A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). J Clin Oncol. 2010;28[suppl]:7s: Abstract LBA2002.
35. Wick W, Engel C, Combs SE, et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved field radio-therapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). J Clin Oncol. 2010;28[suppl]:7s: Abstract LBA2001.
36. Weller M, Hentschel B, Felsberg J, et al. Profound predictive impact of MGMT promoter methylation in glioblastoma of the elderly. J Clin Oncol. 2011;29[suppl]:Abstract 2001.
37. Preusser M, Janzer RC, Felsberg J, et al. Anti-O -methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multi-forme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-532.
38. Sciuscio D, Diserens AC, van Dommelen K, et al. Extent and pat-terns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres. Clin Cancer Res. 2011;17:255-266.
39. Wick W, Steinbach JP, Combs SE, et al. H6Q-MC-S039: Enzastaurin (LY317615) before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy in subjects with newly diagnosed glioblastoma-a multicenter, open-label, uncontrolled phase II study. J Clin Oncol. 2011;29[suppl]:Abstract 2007.
40. Stupp R, Hegi ME, Neyns B, et al. Phase I//IIa study ofcilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diag-nosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.
41. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. NEngl JMed. 2009;360:765-773.
42. Kloosterhof NK, Bralten LBC, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011;12:83-91.
43. Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concen-tration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. [published online ahead ofprint September 12, 2011].
44. Nagarajan R, Thomas MA, Pope WB, et al. Detection of 2-hydroxyglutarate in mutant brain tumors in vivo using proton magnetic resonance spectro-scopy. Proc Intl Soc Mag Reson Med. 2011;19:184.
45. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 func-tion, and impair hematopoietic differentiation. Cancer Cell. 2010;18: 553-567.
46. Lai A, Tran A, Nghiemphu PL, et al. Phase II study ofbevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
47. 18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;11:861-870.
48. Sorensen AG, Batchelor TT, Zhang WT, et al. A ''vascular normaliza-tion index'' as potential mechanistic biomarker to predict survival after a single dose ofcediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296-5300.
49. Fan X, Khaki L, Zhu TS, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neuro-spheres and xenografts. Stem Cells. 2010;28:5-16.